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Introduction
For some forms of life, oxalate is an essential metabolite. For
others, including humans, it is a toxic, non-metabolizable waste
product eliminated by the kidney.1 Toxicity arises from its
tendency to form extremely insoluble and virtually indestructi-
ble calcium oxalate crystals, which damage cells directly and
obstruct the lumen of renal tubules. While some urine oxalate in
healthy individuals is derived from intestinal absorption,2 most
is formed endogenously from its chemical precursor, glyoxylate,
by the action of the peroxisomal enzyme, glycolate oxidase (GO).
The primary role of this enzyme is to oxidize glycolate; its ability
to further oxidize glyoxylate to oxalate is a regrettable conse-
quence of its broad substrate specificity. Glyoxylate escaping
from peroxisomes into cytosol can also be oxidized to oxalate by
the ubiquitous cytosolic enzyme, lactate dehydrogenase (LD).1
The major determinant of oxalate production is thus the
steady-state level of glyoxylate, which in turn depends on its
relative rates of formation and consumption. It is formed from
oxidative deamination of glycine catalysed by D-amino acid
oxidase or from glycolate by glycolate oxidase, while its removal
is effected by transamination back to glycine by alanine
glyoxalate aminotransferase (AGT), or egress from the peroxi-
some and reduction to glycolate by glyoxylate reductase (GR). A
defect in the catalytic activity or appropriate subcellular localiza-
tion of either of these two latter enzymes inevitably leads to an
accumulation of glyoxylate, and its conversion to oxalate. Clini-
cal disorders due to defects in either enzyme have been
well-characterized, and are referred to as primary hyperoxaluria
(PH) types I and II, respectively.1 The metabolic pathways
involved in oxalate production are illustrated in Fig. 1.
Of the two disorders, type I (AGT deficiency) is the more
common and clinically severe. It is characterized by progressive
renal damage due to deposition of insoluble calcium oxalate
within the kidney substance and as kidney stones. As renal func-
tion deteriorates, the kidney is no longer able to excrete oxalate,
and it deposits throughout the body, a condition termed systemic
oxalosis; typical sites include bone, heart and blood vessel walls.
Figure 2 shows a bone biopsy from a 9-year-old child with
primary hyperoxaluria type I. When stained with haematoxylin
& eosin (A), calcium oxalate crystals appear as greyish masses
with radiating spicules. Multinucleated foreign body giant cells
can be seen closely apposed to the crystals, in a (vain) attempt to
digest and remove them. When viewed under polarizing light
(B), birefringent calcium oxalate crystals stand out as blue and
yellow against the red background of normal tissue. The latter
method of examination is more sensitive insofar as it clearly
shows multiple small crystals not readily apparent by conven-
tional staining. Over 80% of PH type I patients die by the age of
20 years. The only currently effective treatment for this devastat-
ing disorder is combined kidney and liver transplantation, the
latter being necessary because AGT expression is confined to
that organ.
PH type II, due to a defect in the cytosolic enzyme glyoxylate
reductase (GR), runs a more benign clinical course, with symp-
toms usually confined to recurrent kidney stones. Idiopathic cal-
cium oxalate stone disease is another disorder, in which urinary
excretion of oxalate is excessive and leads to kidney stone forma-
tion.3, 4 Although far commoner than the above two monogenic
disorders, the contribution of the genetic and environmental
factors implicated in its causation are yet to be ascertained.5
Acute kidney damage from calcium oxalate deposition can also
occur after ethylene glycol ingestion.6 This compound is the
active ingredient of anti-freeze and brake fluid, and is sometimes
added illegally to alcoholic beverages. It is oxidized by hepatic
alcohol and aldehyde dehydrogenase to glycolate, which under-
goes further oxidation to oxalate,7 as outlined in Fig. 1. Since in all
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Calcium oxalate is the most frequent cause of kidney stones, and is
responsible for the damage to kidneys and other organs observed
in inherited disorders of oxalate metabolism. Most oxalate pro-
duced in the body is derived from its metabolic precursor,
glyoxylate. Thus, any means of scavenging glyoxylate to a
non-toxic product, thereby diverting it away from oxalate synthesis,
has considerable therapeutic implications. Here we show that
aminoguanidine, a compound with a proven safety record and used
for many years to prevent long-term complications of diabetes,
binds glyoxylate covalently and reduces its conversion to oxalate
by human liver- and lymphocyte-derived cell lines by >90%. We
propose that scavenging glyoxylate with aminoguanidine or its
congeners may provide a means of reducing oxalate production in
vivo, and advocate the tissue culture system described here as a
convenient means for testing such agents in vitro. A serendipitous
finding to emerge from our study was the abiotic and strongly
pH-dependent formation of oxalate from ascorbate, which has
implications for the contribution of ascorbate to urine oxalate
excretion.
Fig. 1. Metabolic pathways involved in oxalate formation. DAO = D-amino acid
oxidase; AGT = alanine glyoxylate transaminase; GO = glycolate oxidase; GR =
glyoxylate reductase; LD = lactate dehydrogenase; ADH = alcohol dehydrogenase;
ALD = aldehyde dehydrogenase; * and # indicate the steps defective in primary
hyperoxaluria types I and II, respectively.
conditions listed above oxalate is directly derived from glyo-
xylate, it follows that reduction of the glyoxylate pool by chemi-
cal means in vivo should decrease endogenous oxalate produc-
tion and ameliorate its attendant tissue damage. There is
experimental evidence that glyoxylate is highly toxic in its own
right.8
Aminoguanidine has been used for several years to prevent
the visual, renal and microvascular degeneration associated
with diabetes.9–11 Its side effects are minor, being confined to nau-
sea, headache and impaired pyridoxine absorption; the last is
readily amenable to dietary supplementation with this vitamin.
It is believed to act by trapping glucose-derived dicarbonyl com-
pounds such as 3-deoxyglucosone that cross-link long-lived
structural proteins, including lens crystallin, collagen and
elastin.12,13 Encouraged by its proven safety record, which would
facilitate its use for a novel clinical application, we explored the
ability of aminoguanidine to react with the carbonyl group of
glyoxylate. We present evidence for covalent binding of
aminoguanidine to glyoxylate, and demonstrate the ability of
aminoguanidine at low millimolar concentrations to profoundly




HepG2 cells were grown as adherent monolayers in Dulbecco’s mini-
mal essential medium (DMEM) supplemented with 10% foetal calf
serum at 37°C in the presence of 10% CO2. For testing their ability to
form oxalate, cells were trypsinized, transferred to 3.5-cm wells in
multi-well plates and incubated as described above. Glyoxylate and/or
aminoguanidine was added from sterile concentrated stock solutions to
give the desired final concentration. Lymphoblasts were derived by
Epstein-Barr virus transformation of peripheral lymphocytes obtained
from donors not known to suffer from disorders of oxalate metabolism.
They were grown as a suspension under the same conditions as HepG2
cells.
[3H]thymidine uptake
HepG2 cells were incubated for 4 h at 37°C in 1 ml Hank’s balanced salt
solution (HBSS) containing 1 µCi [methyl-3H]thymidine, 87 Ci/mmol.
Cells were then washed 3 times with 1 ml 5% trichloracetic acid, DNA
was solubilized in 0.5 ml 0.1 M NaOH, and the radioactivity incorporated
was measured in a -scintillation counter.
Oxalate assay
For most of the oxalate measurements, we used a method developed
in-house that is based on precipitation of added radio-labelled calcium.
Briefly, 10 µl of a 4 µCi/ml solution of [45Ca]Cl2 (0.1–1.0 mCi/mmol,
Amersham Biosciences) was added to 1 ml of medium, followed by 10 µl
of a 0.2 M calcium oxalate (CaOx) suspension to saturate the medium
with respect to CaOx and thereby facilitate precipitation of [45Ca]Ox.
After 16 h at 4°C, tubes were centrifuged at 7000 × g for 10 min, and the
supernatant carefully aspirated and discarded. The CaOx pellet was
dissolved in 0.1 ml of 10 M HCl, transferred to a counting vial and pooled
with 2 × 0.1 ml water washes to ensure quantitative transfer. Radioactiv-
ity was measured in a -scintillation counter, and compared with that
obtained for an oxalate standard curve, generated by adding known
amounts of oxalate to 1 ml aliquots of fresh medium to give a final
concentration ranging from 0 to 0.6 mM. Concerns that exchange of un-
labelled calcium in the CaOx suspension with 45Ca would lead to high
background counts were dispelled by low blank counts routinely
obtained in standard curves (<5% of the counts for the highest oxalate
standard), indicating a negligibly slow rate of exchange.
We also used a commercially available oxalate oxidase-based kit
designed for measurement of oxalate in urine (Sigma Diagnostics).
Briefly, 50 µl aliquots of media or urine were mixed with an equal volume
of 10 mM EDTA to free oxalate from complexes with calcium. A spatula
tip of activated charcoal (~10 mg) was added, mixed for 5 min, then
centrifuged to remove potential inhibitors of subsequent enzymatic
steps; 2 µl supernatant was mixed with 10 µl of a combined reagent con-
taining oxalate oxidase (300 U/l), peroxidase (10 000 U/l), 3-(dimethyl-
amino)benzoate (DMAB) (3 mM) and 3-methyl-2-benzothiazolinone
hydrazone (MBTH) (0.2 mM). Oxalate present was oxidized by oxalate
oxidase to CO2 and hydrogen peroxide, which then oxidized DMAB and
MBTH in the presence of peroxidase to yield a coloured indamine dye.
Absorbance at 595 nm was measured on a Nanodrop® spectrophoto-
meter, and compared to a similarly treated set of aqueous oxalate
standards of 0, 0.2, 0.4 and 0.6 mM. The Nanodrop® was capable of read-
ing absorbance of samples as small as 1 µl, which made the use of the
costly Sigma kit reagents economically feasible.
Spectrophotometric assay for residual glyoxylate
Glyoxylate (1 mM) was incubated with aminoguanidine at concentra-
tions varying from 0 to 20 mM in 50 mM phosphate buffer (pH 7.4). After
30 min at 37°C, 40 µl phenylhydrazine (0.5 M) was added, and 30 s later a
40 µl aliquot of reaction mixture was diluted to 1.2 ml with phosphate
buffer and the optical density read at 324 nm (A324 nm) against a reagent
blank consisting of phosphate buffer alone subjected to the identical
procedure.
Results
We initially studied the interaction of pure solutions of glyo-
xylate and aminoguanidine in vitro. Figure 3 shows the effect of
aminoguanidine on free glyoxylate concentration. Glyoxylate
(1 mM) was incubated with varying concentrations of amino-
guanidine for 30 min at 37°C, then residual glyoxalate deter-
mined spectrophotometrically by its reaction with phenyl-
hydrazine. Results are expressed as % of absorbance recorded in
the absence of aminoguanidine. Failure of A324 nm to fall to zero
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Fig. 2.Histological appearance of oxalate crystals.A bone biopsy from a 9-year-old
child with primary hyperoxaluria type I, was stained with haematoxylin & eosin (A),
or viewed under polarizing light (B). When stained with H&E, calcium oxalate
crystals appear as discrete spiculated greyish masses with tightly apposed
multinucleated foreign body giant cells clustered on their surface, attempting to
digest them. Under polarizing light, bone matrix and marrow appears red, whereas
birefringent calcium oxalate crystals appear blue and yellow. Magnification ×200.
with increasing aminoguanidine we attribute to reversibility of
the glyoxylate–aminoguanidine reaction, in that the phenyl-
hydrazine indicator reagent, present in vast molar excess, com-
peted with aminoguanidine for glyoxylate binding. This
method therefore underestimated the extent of binding.
The reaction between glyoxylate and aminoguanidine resulted
in characteristic changes in the UV absorption spectrum. Figure
4 shows a time course for the development of an absorption peak
at 240 nm observed upon mixing glyoxylate with amino-
guanidine, both at an initial concentration of 0.5 mM.
To characterize the product(s) formed between glyoxylate and
aminoguanidine further, the two compounds, both at 2 mM,
were incubated overnight at 37°C, then analysed by positive
mode electrospray mass spectroscopy (ESMS). A 131-Da prod-
uct, consistent with a Schiff base adduct between glyoxylate
(74 Da) and aminoguanidine (75 Da) (74 + 75 – 18 = 131) was the
principal species observed (Fig. 5A). An aliquot of reaction mix-
ture was analysed by strong cation-exchange HPLC on a PolyLC
polysulphoethyl A column, and UV-absorbing material eluting
as a single major peak (results not shown) was analysed by
ESMS. A small 131-Da peak was observed, alongside a number of
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Fig. 3. Decrease in free glyoxylate concentration by aminoguanidine. Glyoxylate
(1 mM) was incubated with varying concentrations of aminoguanidine from 0 to
20 mM for 30 min at 37°C, then residual glyoxylate was measured as its phenyl-
hydrazone adduct by absorption at 324 nm.
Fig. 4. UV absorption spectrum of the glyoxylate–aminoguanidine complex.
Glyoxylate and aminoguanidine were mixed and the UV-absorption spectrum
monitored over the next 6 h. Initial concentration of both reactants was 0.5 mM.
Fig. 5. Characterization of the complex formed between glyoxylate and aminoguanidine by mass spectroscopy. Glyoxylate and aminoguanidine, both at 2 mM, were
incubated together for 16 h at 37°C, then analysed directly by electrospray mass spectroscopy, either directly (A), or after purification of UV-absorbing material by cation
exchange HPLC (B). The arrow indicates the 131-Da fragment expected for a Schiff-base adduct between glyoxylate and aminoguanidine.
larger molecular weight species of undetermined structure, pre-
sumably representing polymerization products of the initial
Schiff base adduct (Fig. 5B). Our interpretation of these data is
that glyoxylate and aminoguanidine initially reacted to form a
Schiff base, which subsequently polymerized to yield the
UV-absorbing material observed spectroscopically.
We next examined whether cultured human cells were able to
convert exogenous glyoxylate to oxalate and, if so, whether
aminoguanidine inhibited this conversion by sequestering
glyoxylate. We initially chose HepG2 cells, since these are
derived from liver, the organ primarily responsible for oxalate
production in vivo. Confluent monolayers of HepG2 cells were
incubated in medium containing glyoxylate from 0 to 2 mM,
either in the absence or presence of 2 mM aminoguanidine, then
the oxalate concentration in the medium was measured as
described under Methods. HepG2 cells were indeed able to
convert glyoxylate to oxalate; by 48 h, 15–20% of glyoxylate
initially added to control cells had been converted to oxalate.
Inclusion of aminoguanidine reduced oxalate production by
>90% (Fig. 6). In a parallel experiment, uptake of [3H]thymidine
by HepG2 cells was determined as a measure of cell viability.
Uptake decreased progressively in cells exposed to increasing
concentrations of glyoxylate; this decrease was abrogated by
inclusion of aminoguanidine (Fig. 7). These results are consistent
with the notion that aminoguanidine sequesters glyoxylate,
thereby preventing both its conversion to oxalate and any
adverse effect it may exert on cell viability. Whether glyoxylate
induces cell toxicity directly, as has been proposed,8 or through
its conversion to oxalate, remains to be ascertained.
To check whether ability to convert glyoxylate to oxalate was
confined to liver-derived cell lines, we performed comparable
experiments on lymphoblasts transformed by Epstein-Barr
virus. As shown in Fig. 8, four independent lymphoblast cell
lines were able to convert approximately 5% of the glyoxylate
initially present to oxalate in 48 h. Inclusion of an equimolar
amount of aminoguanidine (2 mM) reduced oxalate production
by 90%, similar to our findings with HepG2 cells (results not
shown).
Encouraged by these in vitro results, we undertook a pilot
experiment to ascertain whether aminoguanidine affected
oxalate excretion in healthy human subjects. One of us (P.B.)
ingested aminoguanidine, 100 mg 3-hourly for 24 h, and com-
pared urinary oxalate excretion during that period with the 24 h
immediately before and after. No untoward side effects were
experienced, but, rather disappointingly, neither was any signif-
icant change in oxalate excretion observed (results not shown).
We next tested whether HepG2 cells were able to produce
oxalate from substrates other than glyoxylate. Neither glycine,
glycolate nor ethylene glycol, tested at concentrations up to
50 mM, served as oxalate precursors (results not shown). Ascor-
bate, however, was converted to oxalate even more efficiently
than was glyoxylate (>20% conversion within 24 h). Rather
unexpectedly, oxalate production did not require the presence of
cells, nor was it affected by aminoguanidine, iron chelation, or
exclusion of foetal calf serum from the medium (Fig. 9), indicat-
ing that it was non-enzymatic, non-iron-dependent and did not
proceed via a reactive aldehyde intermediate such as glyoxylate.
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Fig. 6. Glyoxylate conversion to oxalate by HepG2 cells, and its inhibition by
aminoguanidine. HepG2 cells were incubated for 48 h with glyoxylate at the con-
centrations indicated, either in the absence (open bars) or presence (filled bars) of
2 mM aminoguanidine, then oxalate concentration of the medium was measured.
Bar height represents the mean of triplicate assays; error bars denote the range.
Fig. 7.Glyoxylate toxicity to HepG2 cells reversed by aminoguanidine.HepG2 cells
were incubated for 48 h with glyoxylate at the concentrations indicated, either in the
absence (open bars) or presence (filled bars) of 3 mM aminoguanidine. Medium
was replaced with fresh medium containing [3H]thymidine, then incubated for a
further 4 h. Incorporation of [3H]thymidine into acid-insoluble material (DNA) was
determined and expressed as a percentage of the [3H]thymidine added.Bars repre-
sent the mean of triplicate measurements, error bars the range.
Fig. 8. Oxalate production from glyoxylate by transformed lymphoblasts. Epstein-
Barr transformed lymphoblasts prepared from four different human donors (L1–L4)
were incubated for 48 h without (closed bars) or with (open bars) 2 mM glyoxylate,
then the medium was assayed for oxalate. Bars represent the mean of duplicate
measurements, error bars the range.
Fig. 9. Ascorbate to oxalate conversion unaffected by iron chelation, amino-
guanidine, or serum.DMEM, devoid of cells or foetal calf serum, was supplemented
with ascorbate, desferrioxamine and/or aminoguanidine as detailed above, and
incubated at 37°C in the absence of cells for the times indicated. Oxalate concen-
tration was then measured. Samples were processed in duplicate; bar height
reflects the mean, error bars the range.
No oxalate was detected when ascorbate-supplemented DMEM
was analysed immediately, excluding the possibility of oxalate
contamination of the ascorbate used (Fig. 9). Oxalate formation
was, however, critically dependent on the nature of the tissue
culture medium. It proceeded rapidly in DMEM, but not at all in
HBSS. In a search for the crucial abiotic factor promoting
non-enzymatic conversion of ascorbate to oxalate, we tested six
commonly used tissue culture media, and found that the only
component of media that correlated with conversion efficiency
was [HCO3
–]. Figure 10 shows the exponential relationship be-
tween conversion efficiency and operating pH of the medium
when equilibrated with 10% CO2.
To confirm that enhanced conversion of ascorbate to oxalate in
DMEM could be ascribed to its high operating pH, we examined
conversion efficiency in three different media (DMEM, RPMI
and Hams-F10) at pH values ranging from 6 to 8. For this experi-
ment, the commercial oxalate oxidase method was used for
measuring oxalate. As is apparent from Fig. 11, there was a
marked and equivalent pH dependence of oxalate formation in
all three media, with approximately 10-fold greater oxalate
formation at pH 8 than at pH 6. Interestingly, negligible oxalate
accumulated when water was substituted for medium, pointing
to a requirement for some unknown component present in all
three media. This component must also be present in urine, since
urine exhibited the same pH dependence of oxalate formation.
The appreciable amount of oxalate measured in urine incubated
at pH 6, compared with the culture media, we attribute to oxa-
late present in urine ab initio, rather than that formed during
incubation. This experiment also indirectly served to validate
the in-house oxalate method, insofar as it yielded the same pH
dependence and comparable absolute values for oxalate forma-
tion from ascorbate as did the experiment depicted in Fig. 10,
when the in-house method was employed.
Discussion
Various treatment modalities have been tried in primary
hyperoxaluria in an attempt to minimize calcium oxalate deposi-
tion in the urinary tract. Reducing dietary intake by excluding
oxalate-rich foods such as spinach and rhubarb has limited
value, since over 50% of urine oxalate is derived from endoge-
nous production rather than from intestinal absorption.2
Attempts to reduce urinary calcium by dietary calcium restric-
tion are counterproductive, as dietary calcium binds oxalate in
the bowel lumen, thereby preventing its absorption.2,14 Reducing
the whole body oxalate pool with oxalate degrading enzymes,
such as oxalate oxidase or oxalate decarboxylase entrapped in
dialysis membranes or red cell ghosts, has been tried, but
remains largely experimental.15
The recognition that metabolically generated glyoxylate is the
obligate substrate for endogenous oxalate production has led to
a number of novel approaches to treatment. These include
decreasing glyoxylate synthesis, inhibiting its conversion to
oxalate, or diverting it along alternative chemical pathways. A
number of glycolate oxidase inhibitors, including tris-hydroxy-
methyl-aminomethane (TRIS), reduce glyoxylate formation
from glycolate, and carry the additional advantage of simulta-
neously inhibiting glyoxylate conversion to oxalate.1 Glycolate
formation from glycolaldehyde can be reduced by the aldehyde
dehydrogenase inhibitor, disulfiram, an agent used for alcohol
aversion therapy. Blocking glyoxylate formation from its other
major precursor, glycine, has been attempted by a variety of
means, including dietary glycine restriction, benzoate adminis-
tration, or use of D-amino acids as inhibitors of D-amino acid
oxidase.1
Diverting glyoxylate into alternative chemical pathways has
been explored. Transamination to glycine can be enhanced by
stimulating AGT with pharmacological doses of its vitamin
co-factor, pyridoxine.1 Pyridoxine supplementation has indeed
led to improvement in certain cases of PH type I. Given that AGT
is a peroxisomal enzyme, non-specific stimulation of peroxi-
somal proliferation with drugs such as fibrates has been
attempted, but in humans unfortunately boosts mitochondrial
rather than peroxisomal levels of AGT.1 Non-enzymatic trapping
of glyoxylate as a thiol adduct with cysteine16 or penicillamine17
to form a thiazolidine derivative has also been demonstrated
in vitro. In our study, we showed that aminoguanidine in the low
millimolar concentration range also trapped glyoxylate, thereby
effectively reducing both its inherent toxicity and its conver-
sion to oxalate by cells in culture. Glyoxylate toxicity has been
demonstrated before.8,18 Poldelski et al. showed a decline in cellu-
lar ATP and release of lactate dehydrogenase from isolated renal
tubular cells exposed to glyoxylate, although concentrations of
glyoxylate used in that study,18 namely 13–65 mM, far exceed the
1–3 mM used here. Either HepG2 cells are more sensitive than
renal tubular cells to glyoxylate toxicity, or thymidine incorpora-
tion is a more sensitive reflection of cellular well-being.
The question as to whether glyoxylate serves any useful func-
tion in a cell needs to be addressed. Glyoxylate is a key compo-
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Fig. 10. Dependence of conversion of ascorbate to oxalate on nature of medium.
Six commercially available tissue culture media were supplemented with 2 mM
ascorbate and incubated for 24 h at 37°C in an atmosphere of 10% CO2. Oxalate
concentration and pH of the media were measured at the end of 24 h by the in-
house method, and % ascorbate converted to oxalate plotted as a function of pH.
Fig. 11. pH-dependence of conversion of ascorbate to oxalate in different tissue
culture media and in urine. Three different media, water, or urine were supple-
mented with 5 mM ascorbate and 25 mM HEPES, and pH adjusted by addition of
NaOH. After incubation for 24 h at 37°C, oxalate was measured by the commercial
oxalate oxidase method. DMEM is depicted by horizontal striped bars, RPMI by
hatched bars, Hams-F10 by checked bars, urine by solid bars, and water by open
bars.
nent of the glyoxylate cycle, a modified form of the citric acid
cycle whereby isocitrate is converted via glyoxylate to oxalo-
acetate. This cycle, which allows net carbohydrate synthesis
from fat, was originally believed to be confined to microorgan-
isms and germinating seeds of higher plants. More recently,
however, convincing evidence has been presented of its exis-
tence in mammalian tissues; specifically, neonatal rat liver and
starved adult rat liver, where it assists in maintaining blood
glucose, as well as in rat epiphyseal cartilage after exposure to
vitamin D.19–21 Not surprisingly, enzymes of the cycle are con-
fined to peroxisomes, where glyoxylate is formed. The high Km of
malate synthase for glyoxylate (3 mM)20 is indirect evidence
that glyoxylate may reach millimolar concentrations, at least
within the peroxisome, although levels of glyoxylate in normal
tissues and tissues from patients with primary hyperoxaluria
and ethylene glycol intoxication have, to our knowledge, never
been measured directly.
These encouraging in vitro findings need to be validated
in vivo. Rather disappointingly, ingestion of 100 mg amino-
guanidine 3 hourly over 24 h by one of us (P.A.B.) had little effect
on oxalate excretion. This dose is substantially greater than
the 300 mg/day ingested over 15 months as part of a large clini-
cal trial conducted to assess the efficacy of aminoguanidine on
retarding onset of diabetic nephropathy.22 Plasma levels of
aminoguanidine after the first few doses can be estimated by
assuming a pseudo-steady state, where aminoguanidine enter-
ing the circulation from the gut equals that eliminated by the
kidney. Rate of entry = 100/3 mg/h, whereas rate of elimination
(assuming clearance by glomerular filtration and a glomerular
filtration rate of 100 ml/min) = [A] × 0.1 × 60 = [A] × 6 mg/h,
where [A] = plasma level of aminoguanidine in mg/l. Solving for
[A] yields 5.5 mg/l, or 0.075 mM, which is appreciably lower than
the concentration required, according to Fig. 3, to reduce
glyoxylate substantially. Thus, higher plasma levels of amino-
guanidine (or a more potent aminoguanidine analogue – see
below) will be required to scavenge glyoxylate effectively in vivo.
Another possible reason for failure of aminoguanidine to lower
glyoxylate in healthy subjects might be its inability to access the
peroxisome readily, where, under physiological conditions,
glyoxylate oxidation to oxalate occurs. By contrast, in hyper-
oxaluric syndromes accumulated glyoxylate leaks from the
peroxisome into the cytosol, where it is oxidized to oxalate by
cytosolic lactate dehydrogenase,23 and where it might be more
accessible to scavenging by aminoguanidine.
In terms of the fate of the aminoguanidine–glyoxylate complex
and its polymerization products, we predict that, by virtue of
their water solubility, they will not accumulate or dissociate, but
will rapidly be cleared by glomerular filtration, thereby deplet-
ing the whole body glyoxylate pool. Moreover, aminoguanidine
might not be the most effective glyoxylate scavenging agent; a
recent study indicated that the drug, hydralazine, scavenges
acrolein (CH2=CH-CHO), a toxic aldehyde formed during lipid
peroxidation, more than three times faster than an equimolar
concentration of aminoguanidine.24 Preliminary results in our
laboratory confirm its superior efficacy with respect to
glyoxylate (results not shown).
While screening other potential substrates for oxalate produc-
tion by HepG2 cells, we observed that ascorbate was readily con-
verted to oxalate in certain media, and that conversion was,
rather unexpectedly, not dependent on the presence of cells or
serum. On testing media of diverse composition for ability to
support oxalate generation from ascorbate, the only component
that consistently correlated with conversion efficiency was
bicarbonate, and thus medium pH. This finding may have a
bearing on the contribution of dietary ascorbate to urinary
oxalate excretion in vivo, or even ex vivo as an analytical artefact.25
Although the literature abounds with conflicting reports regard-
ing the importance of ascorbate as an oxalate precursor26 in vivo,
the impact of variations of pH within the physiological range on
the non-enzymatic conversion of ascorbate to oxalate has, to our
knowledge, not been explored. A recent study examined the
non-enzymatic conversion of radiolabelled ascorbate to oxalate
and L-threonate by Rosa cells, and identified several novel inter-
mediates, including 4-O-oxalyl-L-threonate, but not glyoxylate,
in the process.7 That study implicated heat-stable but otherwise
unidentified components of the medium as enhancers of oxalate
formation, but did not explore the effect of pH. Our finding that
conversion of ascorbate to oxalate is unaffected by amino-
guanidine supports the contention that it proceeds via chemical
intermediates not including glyoxylate, thus making it unlikely
that aminoguanidine will affect oxalate production from
ascorbate in vivo.
Conclusions
We show here that glyoxylate is readily converted to oxalate by
both hepatic and non-hepatic cell lines, and that such conver-
sion is strongly inhibited by aminoguanidine. As rationale, we
provide biochemical evidence for covalent binding between
glyoxylate and aminoguanidine, and propose that amino-
guanidine, or a more potent derivative thereof, holds promise as
a drug for reducing oxalate production in various forms of
oxalate overproduction and calcium oxalate stone disease. We
furthermore demonstrate the critical importance of small pH
change within the physiological range for non-enzymatic oxida-
tion of ascorbate to oxalate, and note the implications this might
have for the contribution of ascorbate to oxalate excretion in vivo.
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